A Phase I, Partially Blinded, Randomized, Placebo Controlled, Active Comparator Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Post-menopausal Women After Daily Oral Doses of PTH134.
Phase of Trial: Phase I
Latest Information Update: 12 May 2011
At a glance
- Drugs Teriparatide; Teriparatide
- Indications Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 12 May 2011 Additional location (Germany) identified as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.